Eli Lilly

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial
Reuters
Eli Lilly
psoriatic arthritis
Taltz
AbbVie
Humira
clinical trials
Flag link:
Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets
Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets
Endpoints
Eli Lilly
painkillers
Hydra Biosciences
TRPA-1
Flag link:
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Fierce Pharma
Sanofi
Lantus
Eli Lilly
Boehringer Ingelheim
Mylan Labs
generics
diabetes
insulin
basal insulin
Flag link:
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug
Fierce Biotech
Eli Lilly
AC Immune
Alzheimer's disease
tau
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
Eli Lilly's former drug yields Phase 2 win for Vanda Pharma
Eli Lilly's former drug yields Phase 2 win for Vanda Pharma
Biopharma Dive
Vanda Pharmaceuticals
gastroparesis
clinical trials
Eli Lilly
tradipitant
Flag link:
Rising fear among Asians leads Eli Lilly to rethink employee groups
Rising fear among Asians leads Eli Lilly to rethink employee groups
Indianpolis Business Journal
Eli Lilly
Flag link:
Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials
Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials
Fierce Biotech
Brickell Bio
Eli Lilly
Robert Brown
dermatology
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Eli Lilly Could Sell Some Older China Assets for up to $300 Million
Eli Lilly Could Sell Some Older China Assets for up to $300 Million
BioSpace
Eli Lilly
China
Flag link:
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer
Fierce Pharma
China MediTech
Elunate
Eli Lilly
China
non-small cell lung cancer
Flag link:
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
Biopharma Dive
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Flag link:
Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache
Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache
Fierce Pharma
Eli Lilly
Emgality
cluster headaches
FDA
breakthrough therapies
Flag link:
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
EP Vantage
Eli Lilly
drug development
Alzheimer's disease
BACE inhibitors
Flag link:
Biotech Eli Lilly files for FDA approval of migraine drug lasmiditan
Biotech Eli Lilly files for FDA approval of migraine drug lasmiditan
Fierce Biotech
Eli Lilly
migraines
FDA
Lasmiditan
Flag link:
Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardiovascular Health
Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardiovascular Health
BioSpace
Viagra
Pfizer
Cialis
Eli Lilly
erectile dysfunction
cancer
Cardiovascular
drug repurposing
Flag link:
Fresh from Eli Lilly deal, NextCure bags $93M for clinical push
Fresh from Eli Lilly deal, NextCure bags $93M for clinical push
Fierce Biotech
NextCure
NC318
Eli Lilly
Flag link:
Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s
Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s
Endpoints
Eli Lilly
Alzheimer's disease
BACE inhibitors
Flag link:
Despite Trulicity success, Lilly can't escape diabetes concerns
Despite Trulicity success, Lilly can't escape diabetes concerns
Biopharma Dive
Eli Lilly
diabetes
earnings
Trulicity
Flag link:
Eli Lilly Commits $40M to NextCure in Hunt for New Cancer Drugs
Eli Lilly Commits $40M to NextCure in Hunt for New Cancer Drugs
Xconomy
Eli Lilly
NextCure
cancer immunotherapy
drug development
Flag link:

Pages